StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Evofem Biosciences's revenue for the twelve months ending Jun 30, 2026 was $18.05M, up 4.5% year over year. For fiscal 2025 it was $20.18M, up 4.2% from the year before. The highest annual figure on record is $20.18M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$20.18M+4.2%
FY2024Dec 31, 2024$19.36M+6.3%
FY2023Dec 31, 2023$18.22M+8.2%
FY2022Dec 31, 2022$16.84M+104.2%
FY2021Dec 31, 2021$8.24M+1748.4%
FY2020Dec 31, 2020$446.00K–
FY2019Dec 31, 2019$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.63M-45.4%
Q1 FY2026Mar 31, 2026$899.00K+6.4%
Q4 FY2025Dec 31, 2025$9.56M+34.6%
Q3 FY2025Sep 30, 2025$4.95M+10.1%
Q2 FY2025Jun 30, 2025$4.83M+16.0%
Q1 FY2025Mar 31, 2025$845.00K-76.5%
Q4 FY2024Dec 31, 2024$7.10M+189.0%
Q3 FY2024Sep 30, 2024$4.50M-22.6%
Q2 FY2024Jun 30, 2024$4.16M+2198.3%
Q1 FY2024Mar 31, 2024$3.60M-43.4%
Q2 FY2023Jun 30, 2023$2.46M-59.3%
Q1 FY2023Mar 31, 2023$5.81M+36.7%
Q4 FY2022Dec 31, 2022$181.00K-94.9%
Q3 FY2022Sep 30, 2022$6.37M+272.1%
Q2 FY2022Jun 30, 2022$6.03M+224.9%
Q1 FY2022Mar 31, 2022$4.25M+284.7%
Q4 FY2021Dec 31, 2021$3.57M+2025.0%
Q3 FY2021Sep 30, 2021$1.71M+515.8%
Q2 FY2021Jun 30, 2021$1.86M–
Q1 FY2021Mar 31, 2021$1.11M–
Q4 FY2020Dec 31, 2020$168.00K–
Q3 FY2020Sep 30, 2020$278.00K–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–

More Evofem Biosciences figures

See a number that looks wrong?